# First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07265622/  
OnCo record `nct07265622` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of 7MW4911 in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.

## Summary

First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07265622 by Mabwell (Shanghai) Bioscience Co., Ltd., with 200 participants planned, started 2025-11-12 and due to reach its primary completion in 2027-07. Interventions recorded: 7MW4911.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07265622
- Phase: 1/2
- Setting: A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of 7MW4911 in Patients With Advanced Solid Tumors
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT07265622: https://clinicaltrials.gov/study/NCT07265622

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07265622.json